Early detection of cancer prolongs life. The team at bioAffinity Technologies has seen this firsthand. Our brothers, sisters, parents, friends and patients, and many of us personally, have benefited from early cancer detection. We have seen the triumph when cancer is beaten back. We also have seen the ravages of cancer when it cannot be beaten. We have responded by equipping ourselves with education, skill and a passion to fight this dreaded disease.
Our team is developing tests that can diagnose cancer at its earliest stages when it is most treatable. We are unlocking the potential of a compound that preferentially binds to cancer cells and causes them to fluoresce red under special light. It is a simple idea with a profound result. Catch cancer early. Treat cancer when therapies are most effective.
The scientists, physicians, regulatory and reimbursement experts, financiers, lawyers, marketers, executives and investors who contribute to bioAffinity Technologies are people affected by cancer who know that by unlocking our personal potential, we can make scientific discoveries that give others the opportunity to live longer and more enjoyable lives. We share a commitment to continual scientific exploration and collaboration, and applying the discoveries that result from our work toward the development and commercialization of patient-friendly tests that accurately diagnose early-stage cancer.